MigVax-101
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Routes of administration | Oral |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg.png){kind=small} COVID-19 portal |
MigVax-101 is a COVID-19 vaccine candidate developed by Oravax Medical.[1][2][3]
References
- ^ Jaffe-Hoffman M (11 June 2021). "Israeli oral COVID-19 vaccine en route to clinical trials". The Jerusalem Post. Retrieved 2 November 2021.
- ^ Jaffe-Hoffman M (22 July 2021). "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post. Retrieved 2 November 2021.
- ^ "Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial". Cision PR News Wire. 29 October 2021. Retrieved 2 November 2021.
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.